Merck Sharp & Dohme Corp. v. Everest Organics Limited

In the high-stakes world of pharmaceuticals, the gap between a patent expiring and a generic launch can be worth hundreds of crores. When a competitor begins preparing to commercialize a patented molecule, the original innovator has only one real weapon: the courts. This case shows exactly how that weapon is deployed when time is running out and the threat of irreparable harm looms large.

Merck Sharp & Dohme Corp. and another plaintiff, the innovators behind the molecule Sitagliptin, held registered Patent No. 209816 covering that compound. Sitagliptin is a well-known pharmaceutical molecule used in diabetes treatment, and the patent represented years of research, clinical trials, and regulatory investment. The defendant, Everest Organics Limited, was allegedly developing and preparing to commercialize a product that the plaintiffs believed infringed their patent rights. Rather than wait for an actual launch to seek relief, Merck moved the court proactively, filing a suit for permanent injunction to stop the alleged infringement in its tracks.

The plaintiffs argued that Everest Organics was gearing up to bring an infringing product to market, which would directly violate their exclusive rights under Patent No. 209816. They presented enough material to convince the court that a strong prima facie case of infringement existed, and that waiting until the product was actually launched would cause them irreparable harm that no monetary award could later undo. The defendant, having been served notice of an ex-parte application, had limited opportunity to counter at this stage. The core legal friction was simple but urgent: should the court step in before any commercial sale had even occurred, based solely on the plaintiffs' prima facie showing and the risk of imminent irreparable loss?

The court was satisfied that the plaintiffs had made out a strong prima facie case of patent infringement. It found that the balance of convenience clearly favored Merck, and that the threat of irreparable injury to the patent holder justified immediate intervention. On 8 May 2020, the court granted an ad-interim ex-parte injunction in favor of Merck Sharp & Dohme Corp., restraining Everest Organics Limited from commercializing the allegedly infringing product. The matter was treated as an interim order, meaning the injunction would hold until further hearing, but the immediate effect was decisive: the defendant could not move forward with its planned launch while the dispute was being adjudicated.

For founders and IP professionals in pharma and other patent-driven industries, this case is a clear reminder that the law allows you to act before the damage is done. If you hold a valid patent and you have credible evidence that a competitor is preparing to launch an infringing product, you do not have to wait for the first sale to seek relief. Build a strong prima facie case, demonstrate the likelihood of irreparable harm, and show that the balance of convenience tilts your way. Courts will grant interim injunctions to preserve your exclusive rights, but only if you move quickly and present your evidence convincingly. Proactive enforcement, not reactive litigation, is what protects the value of your patent.